Daravita Disclosure Statement Case 114-Cv-01118-UNA

  • Upload
    kevgo

  • View
    22

  • Download
    0

Embed Size (px)

DESCRIPTION

Case 114-Cv-01118-UNADaravita (Alkermes) Patent Infringement Case Against Actavis with respect to the Manufacturing of Generic ZohydroER.ZohydroER is licensed by Zogenix and has exclusivity until fall 2016 by the FDA.

Citation preview

  • 5/20/2018 Daravita Disclosure Statement Case 114-Cv-01118-UNA

    1/2

    IN THE UNITED STATES DISTRICT COURT

    FOR THE DISTRICT OF DELAWARE

    DARAVITA LIMITED,

    Plaintiff,

    v.

    ACTAVIS LABORATORIES FL, INC.,

    ANDRX CORPORATION, ACTAVIS

    PHARMA, INC., and ACTAVIS, INC.,

    Defendants.

    )

    )

    ))

    )

    ))

    )

    ))

    )

    C.A. No. ______________

    DARAVITA LIMITEDS RULE 7.1 DISCLOSURE STATEMENT

    Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, Plaintiff Daravita Limited

    states that it is a subsidiary of Alkermes plc, a publicly held corporation. No company currently

    owns more than 10% of the stock of Alkermes plc.

    MORRIS, NICHOLS, ARSHT & TUNNELL LLP

    /s/ Maryellen NoreikaJack B. Blumenfeld (#1014)Maryellen Noreika (#3208)Jeremy A. Tigan (#5239)

    1201 N. Market Street

    P.O. Box 1347Wilmington, DE 19899-1347

    (302) 658-9200

    [email protected]

    [email protected]@mnat.com

    Attorneys for Daravita Limited

    September 3, 20148498179

    Case 1:14-cv-01118-UNA Document 4 Filed 09/03/14 Page 1 of 1 PageID #: 46

  • 5/20/2018 Daravita Disclosure Statement Case 114-Cv-01118-UNA

    2/2